Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review. Table 1

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force > Topic Index > Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility > Systematic Evidence Review

Intervention	Average-Risk Women*	High-Risk Women*
Breast cancer screening	Annual mammography every 1-2 y beginning at age 40 y³⁶	BRCA mutation carriers: monthly self-examinations beginning by age 18-21 y, annual or semiannual clinician examinations beginning at age 25-35 y, and annual mammography beginning at age 25-35 y³⁷
Ovarian cancer screening	No screening³⁸	BRCA1 mutation carriers: annual or semiannual screening using transvaginal ultrasonography and CA-125 serum levels beginning at age 25-35 y; optional for BRCA2 mutation carriers^37,39
Chemoprevention for breast cancer	None⁴⁰	Women at increased risk for breast cancer as defined by the Gail model and low risk for complications: tamoxifen preventive medication⁴⁰
Prophylactic mastectomy and oophorectomy	None	Women with >2 first-degree relatives with ovarian cancer: offer prophylactic oophorectomy after completion of childbearing or at age 35 y³⁹

* Numbers in parentheses are reference citations.